STOCK TITAN

Director Paul Gendron buys 5,000 InfuSystem (INFU) shares at $8.88

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

InfuSystem Holdings director Paul Andrew Gendron bought additional company stock in the open market. On this Form 4, he reports purchasing 5,000 shares of common stock in an open-market transaction at a weighted average price of $8.88 per share, increasing his direct holdings to 70,000 shares. A footnote explains the price reflects multiple trades on the transaction date and that full trade-by-trade pricing information is available upon request.

Positive

  • None.

Negative

  • None.
Insider GENDRON PAUL ANDREW
Role null
Bought 5,000 shs ($44K)
Type Security Shares Price Value
Purchase Common Stock 5,000 $8.88 $44K
Holdings After Transaction: Common Stock — 70,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares purchased 5,000 shares Open-market purchase reported on Form 4
Purchase price $8.88 per share Weighted average price for the 5,000 shares
Shares owned after trade 70,000 shares Direct ownership following the transaction
Net insider share change 5,000 shares Net-buy direction in transaction summary
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reporting person regulatory
"The reporting person undertakes to provide to the Issuer"
Securities and Exchange Commission regulatory
"the staff of the Securities and Exchange Commission, upon request"
A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GENDRON PAUL ANDREW

(Last)(First)(Middle)
C/O INFUSYSTEM HOLDINGS, INC.
3851 WEST HAMLIN ROAD

(Street)
ROCHESTER HILLS MICHIGAN 48309

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InfuSystem Holdings, Inc [ INFU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026P5,000A$8.88(1)70,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares reported herein were purchased in multiple transactions. The reporting person undertakes to provide to the Issuer, and security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
Remarks:
/s/ Kevin Whitman, Attorney-in-Fact for Paul A. Gendron05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did InfuSystem (INFU) disclose in this Form 4?

InfuSystem disclosed that director Paul Andrew Gendron bought company stock. He reported an open-market purchase of 5,000 shares of common stock, increasing his direct ownership stake to 70,000 shares following the transaction, according to the Form 4 filing details.

How many InfuSystem (INFU) shares did Paul Andrew Gendron buy and at what price?

Paul Andrew Gendron bought 5,000 InfuSystem common shares. The Form 4 shows a weighted average purchase price of $8.88 per share, with a footnote noting that the shares were acquired in multiple transactions at different prices on the same trading day.

What is Paul Andrew Gendron’s InfuSystem (INFU) ownership after this Form 4 trade?

After the reported transaction, Paul Andrew Gendron directly owns 70,000 InfuSystem common shares. This figure, disclosed in the Form 4, reflects his position immediately following the 5,000-share open-market purchase reported for the stated transaction date.

Was the InfuSystem (INFU) Form 4 transaction an open-market purchase or something else?

The Form 4 characterizes the transaction as an open-market purchase. The transaction code is “P,” and the description specifies a purchase in the open market or a private transaction, indicating this was not an option exercise, grant, or tax-related share withholding event.

What does the weighted average price footnote mean in the InfuSystem (INFU) Form 4?

The footnote explains that the reported $8.88 price is a weighted average across multiple trades. It states the shares were bought in several separate transactions and that detailed information on each individual trade price and share amount is available on request from authorized parties.